PF 07257876
Alternative Names: CD47-PDL-1 bispecific antibody - Pfizer; PF-07257876Latest Information Update: 06 Feb 2024
At a glance
- Originator Pfizer
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD47 antigen inhibitors; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Head and neck cancer; Non-small cell lung cancer; Ovarian cancer
Most Recent Events
- 31 Oct 2023 Discontinued - Phase-I for Head and neck cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (Parenteral) prior to October 2023
- 31 Oct 2023 Discontinued - Phase-I for Ovarian cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (Parenteral) prior to October 2023
- 01 Aug 2023 Discontinued - Phase-I for Non-small cell lung cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (Parenteral) (Pfizer website, November 2023)